Acquisition of APIRx
For personal use only
Research priorities
Combined with Incannex, the APIRX drug portfolio
is positioned to yield patent protected products with
marketing approval from regulatory agencies across
a range of therapeutic areas.
The programs outlined on the subsequent slides have been identified as lead assets
for development in the short term.
Lead programs were selected based on their commercial value and ease of path to market,
which is a combination of data that has already been generated and the regulatory strategy.
The goal is to
—
Provide patients with access
to new, evidence-based cannabinoid
therapeutics as soon as possible.
Incannex
Reward investors with faster
path to approved drug product
and revenue.
Shareholder Presentation
12View entire presentation